Rezolute (RZLT) Cash & Equivalents (2010 - 2026)
Rezolute (RZLT) posted Cash & Equivalents of $11.2 million for Q1 2026, down 6.23% sequentially from $11.9 million in Q4 2025, and down 23.29% YoY from $14.6 million in Q1 2025.
Analysis
Rezolute (RZLT) Cash & Equivalents (2010 - 2026) Analysis & Trends
Rezolute has reported Cash & Equivalents for 13 years, with the latest figure at $11.2 million in Q1 2026.
- Quarterly Cash & Equivalents fell 23.29% year-over-year to $11.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.2 million (down 23.29% YoY) and the FY2025 annual result came in at $94.1 million, up 33.68% from the prior year.
- Cash & Equivalents declined to $11.2 million in Q1 2026 per RZLT's latest filing, from $11.9 million in the prior quarter.
- Over five years, Cash & Equivalents peaked at $154.3 million in Q3 2022 and troughed at $5.9 million in Q1 2024.
- A 5-year average of $48.3 million and a median of $14.6 million in 2025 frame the typical range for Cash & Equivalents.
- The sharpest annual moves came in 2023 and 2024: Cash & Equivalents slumped 94.75% in 2023, then surged 338.99% in 2024.
- Over 5 years, Cash & Equivalents stood at $146.7 million in 2022, then plunged by 91.48% to $12.5 million in 2023, then slipped by 28.57% to $8.9 million in 2024, then surged by 33.72% to $11.9 million in 2025, then decreased by 6.23% to $11.2 million in 2026.
- According to Business Quant data, Cash & Equivalents over the past three periods registered $11.2 million, $11.9 million, and $9.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 3.58 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 1.72 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 815.44 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 5.10 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.71 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 811.99 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Rezolute | 477.02 Mn | 477.02 Mn | - | 11.24 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 11.24 Mn |
| Dec 31, 2025 | 11.94 Mn |
| Sep 30, 2025 | 9.10 Mn |
| Jun 30, 2025 | 94.11 Mn |
| Mar 31, 2025 | 14.60 Mn |
| Dec 31, 2024 | 8.93 Mn |
| Sep 30, 2024 | 10.50 Mn |
| Jun 30, 2024 | 70.40 Mn |
| Mar 31, 2024 | 5.93 Mn |
| Dec 31, 2023 | 12.50 Mn |
| Sep 30, 2023 | 8.10 Mn |
| Jun 30, 2023 | 16.04 Mn |
| Mar 31, 2023 | 33.74 Mn |
| Dec 31, 2022 | 146.75 Mn |
| Sep 30, 2022 | 154.32 Mn |
| Jun 30, 2022 | 150.41 Mn |
| Mar 31, 2022 | 63.42 Mn |
| Dec 31, 2021 | 77.40 Mn |
| Sep 30, 2021 | 37.30 Mn |
| Jun 30, 2021 | 41.05 Mn |